OncoMatch/Clinical Trials/NCT06660407
Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer
Is NCT06660407 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for lung non-small cell carcinoma.
This phase II trial tests the safety and effectiveness of the combination of grid radiation therapy and standard of care (SOC) immunotherapy in treating patients with stage IV non-small lung cancer (NSCLC). Conventional radiation therapy treatments typically deliver the same radiation dose to the entire tumor. Spatially fractionated radiation therapy or grid therapy is approved and a technique which permits the delivery of high doses of radiation to small regions of the tumor which can lead to enhanced tumor cell killing. Grid therapy has been shown to produce dramatic relief of severe symptoms, significant tumor regression (decrease in the size of a tumor), and above average local control rates often exceeding those expected with conventionally delivered radiation treatments, all with minimal associated toxicity. Immunotherapy has become combined into treating patients, which has led improvements in survival and quality of life. Immunotherapy is now the cornerstone of SOC therapy for stage IV NSCLC. Grid radiation therapy combined with immunotherapy may be safe and effective in treating patients with stage IV NSCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunotherapy or chemoimmunotherapy — first line
progressing on standard of care first line immunotherapy or chemoimmunotherapy
Cannot have received: stereotactic body radiotherapy
Exception: SBRT > 30 days prior to registration allowed
Patients have not had stereotactic body radiotherapy (SBRT) ≤ 30 days prior to registration
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dL; ANC ≥ 1500/mm^3; Platelet count ≥ 100,000/mm^3
Kidney function
Creatinine ≤ 1.5 x ULN OR GFR > 60 mL/min for patients with creatinine > 1.5 x ULN
Liver function
Total bilirubin ≤ 1.5 x ULN or direct bilirubin ≤ ULN if total bilirubin is > 1.5 x ULN; ALT and AST ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement)
Hemoglobin ≥ 9.0 g/dL (obtained ≤ 15 days prior to enrollment); ANC ≥ 1500/mm^3 (obtained ≤ 15 days prior to enrollment); Platelet count ≥ 100,000/mm^3 (obtained ≤ 15 days prior to enrollment); Total bilirubin ≤ 1.5 x ULN or direct bilirubin ≤ ULN if total bilirubin is > 1.5 x ULN (obtained ≤ 15 days prior to enrollment); ALT and AST ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement) (obtained ≤ 15 days prior to enrollment); Creatinine ≤ 1.5 x ULN OR GFR > 60 mL/min for patients with creatinine > 1.5 x ULN (obtained ≤ 15 days prior to enrollment)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify